Actualités du réseau MIVB-H – JAMRF25

Item: Actualités du réseau MIVB-H – JAMRF25
Rating: 4
Author: PostSingularity Institute

by Pr Sara Lemoinne

Life & Natural Systems Medicine & Health MMedicine and Nursing MJHGastroenterology

🎙 Pr Sara Lemoinne 👥 2K 📅 February 18, 2026 ⏱ 23 min 👁 53 📄 expert opinion 🧭 2026-08-16

Available in: English (current) Français

Keywords

MIVB-Hrare liver diseasesautoimmune hepatitisPBCPSC

Summary

The video is a presentation by Pr Sara Lemoinne at the 2025 Annual Rare Liver Diseases Days, summarizing recent advances and projects of the MIVB-H network. It covers key publications: a nationwide epidemiological study on autoimmune liver diseases using the French health data system (SNDS), showing prevalence and incidence trends, geographic clusters, and increased mortality; a meta-analysis comparing mycophenolate mofetil (MMF) to azathioprine as first-line treatment for autoimmune hepatitis, suggesting MMF superiority; a collaborative study on PSC recurrence after liver transplantation; and phase 2 trials of elafibranor for PSC and linerixibat for PBC pruritus. The presentation also discusses updates to national guidelines (PNDS), the compassionate use of bezafibrate for PBC, and ongoing collaborative projects including the KERS cohort, TAIL2 study, and several PHRC trials (PROUFFASA, BURSAU2, FMT-PSC). Finally, it announces the upcoming DIVA national cohort and the ALBI patient association day.

141 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable updates on recent research and clinical practice in rare liver diseases, with a focus on French collaborative efforts. The argumentation is solid, based on peer-reviewed studies and ongoing trials, though some conclusions are drawn from preliminary data or expert opinion. The speaker clearly explains the significance of each study and its implications for patient care.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to published studies and ongoing clinical trials. The sources are credible, including national health data and multicenter collaborations. The title accurately reflects the content, which is a network update. The presentation is well-structured and evidence-based.

116 words

Title / Content Match

The title accurately reflects the content, which is a summary of recent developments in the MIVB-H network presented at the annual rare liver disease days.

Quality & Reliability

8/10

The presentation is given by a specialist in rare liver diseases, referencing peer-reviewed studies and ongoing clinical trials. The content is consistent with current medical knowledge, though some data are preliminary or based on expert opinion.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

FILFOIE website — Mentioned in the video description as the network's official website.

Concurring Sources

FILFOIE website — Official network site providing context on rare liver diseases.

Contribution & Novelties

The presentation provides an overview of recent research and collaborative initiatives in rare liver diseases, highlighting new epidemiological data, treatment comparisons, and upcoming clinical trials. It emphasizes the importance of national registries and multicenter collaborations.

Pour aller plus loin :

Primary biliary cholangitis — Background on PBC.
Autoimmune hepatitis — Background on AIH.
Primary sclerosing cholangitis — Background on PSC.
Bezafibrate — Drug discussed for PBC.
Mycophenolate mofetil — Drug compared in AIH treatment.

74 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating a presentation that is rich in content and scientifically sound but accessible to a professional audience.

Reliability 8/10

💬 No comments were provided for analysis.